^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    risvutatug rezetecan (GSK5764227)

    i
    Other names: GSK5764227, HS-20093, HS20093, HS 20093, GSK 5764227, GSK-5764227, GSK’227
    Associations

    News

    Trials
    Company:
    GSK, Jiangsu Hansoh Pharma
    Drug class:
    Topoisomerase I inhibitor, B7-H3-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    3d
    A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer (clinicaltrials.gov)
    P2, N=218, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    abiraterone acetate • zeprumetostat (SHR-2554) • AiRuiEn (rezvilutamide) • risvutatug rezetecan (GSK5764227)
    12d
    223054: A Phase 1 study of GSK5764227 in participants with advanced solid tumors (2024-513663-10-01)
    P1, N=152, Recruiting, Glaxosmithkline Research & Development Limited | N=112 --> 152
    Enrollment change
    |
    risvutatug rezetecan (GSK5764227)
    17d
    223675: Evaluation of efficacy and safety of GSK5764227 (alone and in combination) in participants with previously treated advanced unresectable or metastatic gastrointestinal solid tumors (2025-520672-26-00)
    P1/2, N=176, Recruiting, Glaxosmithkline Research & Development Limited
    New P1/2 trial
    |
    risvutatug rezetecan (GSK5764227)
    17d
    223674: Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in Participants with Relapsed Small Cell Lung Cancer (SCLC) (2025-521627-78-00)
    P2/3, N=161, Recruiting, Glaxosmithkline Research & Development Limited
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    topotecan • risvutatug rezetecan (GSK5764227)
    17d
    300148: A Phase 1b/2 study of GSK5764227 in combination with Standard of Care (SoC) or other agents in participants with advanced solid tumors (2025-522274-37-00)
    P1/2, N=15, Recruiting, Glaxosmithkline Research & Development Limited
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • CD276 (CD276 Molecule)
    |
    BRAF V600E • KRAS mutation • MSI-H/dMMR • KRAS G12C • HER-2 amplification • BRAF V600 • KRAS G12
    |
    5-fluorouracil • Xtandi (enzalutamide) • risvutatug rezetecan (GSK5764227)
    17d
    A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P3, N=300, Recruiting, GlaxoSmithKline | Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Sep 2026 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    topotecan • risvutatug rezetecan (GSK5764227)
    22d
    BeeHive: A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, University Health Network, Toronto
    New P2 trial • IO biomarker
    |
    Jemperli (dostarlimab-gxly) • risvutatug rezetecan (GSK5764227)
    2ms
    Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2025 --> Jul 2026
    Enrollment open • Trial primary completion date
    |
    itraconazole • risvutatug rezetecan (GSK5764227)
    2ms
    A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=84, Recruiting, GlaxoSmithKline | Phase classification: P1/2 --> P1 | Not yet recruiting --> Recruiting
    Enrollment open • Phase classification
    |
    Avastin (bevacizumab) • 5-fluorouracil • Xtandi (enzalutamide) • leucovorin calcium • risvutatug rezetecan (GSK5764227)
    3ms
    A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101) (clinicaltrials.gov)
    P1, N=590, Recruiting, GlaxoSmithKline | N=316 --> 590
    Enrollment change • Pan tumor
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • risvutatug rezetecan (GSK5764227)
    3ms
    A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=72, Not yet recruiting, GlaxoSmithKline
    New P1/2 trial
    |
    Avastin (bevacizumab) • 5-fluorouracil • Xtandi (enzalutamide) • leucovorin calcium • risvutatug rezetecan (GSK5764227)
    3ms
    Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=63, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HRS-5041 • risvutatug rezetecan (GSK5764227)